Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]
UXBRIDGE, England, April 17, 2025 /CNW/ -- Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has approved the registration of IFINWIL® (eflornithine) for the treatment of adults and paediatric patients with high-risk neuroblastoma (HRNB), who have responded to prior multiagent, multimodality therapy.1
Neuroblastoma Australia welcomed the news today:
'On behalf of all families of children impacted by neuroblastoma, we welcome the TGA's decision to approve IFINWIL®. We urgently need treatments for children diagnosed with neuroblastoma and this milestone marks a step in the right direction towards a better future for children and their families. We thank the Federal Government for taking action to ensure access and we look forward to continued support for children with aggressive cancers.' said Lucy Jones, CEO Neuroblastoma Australia.
High Risk Neuroblastoma is a rare but aggressive form of cancer, predominantly affecting children and most commonly presenting in the first 5 years of life2. Each year in Australia, approximately 50 children are diagnosed with neuroblastoma, with about half of these cases being classified as high risk neuroblastoma3,4. Neuroblastoma originates in the body's nerve cells (neuroblasts) and typically presents as a primary tumour in the adrenal glands5. It is considered an aggressive tumour because it often spreads to other parts of the body (metastasizes). In most cases, it has spread by the time it is diagnosed5.
'We are committed to improving the lives of children and their families living with high-risk neuroblastoma' said Gus Rudolph, General Manager, Norgine, Australia. 'This rare childhood cancer has devastating consequences for those impacted and while more needs to be done to improve treatment outcomes, we would like to recognise the TGA for their work to-date on this approval. Norgine will continue to engage with the relevant stakeholders to bring IFINWIL® to patients as quickly as possible.'
'This approval, as part of the Project Orbis initiative, represents a vital step forward in ensuring access to innovative cancer treatments for patients around the world,' said Dr. David Gillen, Chief Medical Officer, Norgine. 'By working collaboratively with international regulatory partners, we are able to help bring promising therapies to paediatric patients sooner – a goal that is especially important when time is critical. We're proud to support Project Orbis as we strive to expedite access to high-impact oncology medicines.'
Receiving the TGA approval is an important milestone on the path to realising sustainable and equitable access. IFINWIL® is not currently included on the PBS.
Please refer to the IFINWIL® Consumer Medicines Information (CMI) for full safety information on risks, side effects and precautions including the risk of low red blood cells (anaemia), low neutrophils (blood cells that fight infection), low platelets (clotting cells), increase in liver enzymes, and hearing loss or problems balancing.1
Notes to Editors:
About IFINWIL®
IFINWIL® has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy.6 IFINWIL® is a therapy that blocks an enzyme called ornithine decarboxylase (ODC) responsible for producing polyamines, which are important to tumour growth and development 7.
For more information on IFINWIL®, find the CMI here: IFINWIL Consumer Medicine Information (CMI) or the Therapeutic Goods Administration at https://www.tga.gov.au/ or speak to your healthcare practitioner.
High-Risk Neuroblastoma (HRNB) Treatment Background
Children diagnosed with HRNB undergo an intense treatment regimen that still leaves them vulnerable to relapse and death.8 Although there have been some improvements in survival, children with high risk neuroblastoma still face a 30% chance of recurrence (relapse) within the first 5 years post maintenance, and have an extremely poor prognosis and low likelihood of long term survival9 (e.g. estimates as low as 15% of patients will live for five years after relapsing).10 Avoiding relapse is key to long-term survival, and until now, there have been no approved therapies for the post maintenance treatment period in major markets outside of the United States11.
About Project Orbis
Project Orbis is an initiative (since May 2019) of the US FDA Oncology Center of Excellence (OCE) and provides a framework for concurrent submission and collaborative review of innovative oncology products among international regulatory authorities. It was created with the overarching goal to speed worldwide patient access to innovative cancer therapies. Project Orbis is coordinated by the FDA, and its partners include United Kingdom Medicines and Healthcare Products regulatory Agency (UK MHRA), Australia Therapeutic Goods Administration (TGA), Canada (Health Canada), Singapore (Health Sciences Authority (HSA), Switzerland (Swissmedic), Brazil (Agência Nacional de Vigilância Sanitária (ANVISA), Israel (Ministry of Health).
In April 2024, Norgine submitted an application for approval of eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine's efforts to deliver patient access to eflornithine and bring a further treatment option in the field of paediatric oncology.
About Norgine
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people's lives drives everything we do, and our European experience, fully integrated infrastructure and exceptional partnership approach enable us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped more than 25 million patients around the world in 2022 and generated €530 million in net product sales, a growth of nearly 5% over 2021.
Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
References
Logo - https://mma.prnewswire.com/media/597589/4648918/Norgine_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/norgine-welcomes-tga-registration-in-australia-of-ifinwil-eflornithine-for-adults-and-children-diagnosed-with-high-risk-neuroblastoma-hrnb1-302430883.html
SOURCE Norgine
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Trump's conservative allies warn Congress faces critical 'test' with $9.4B spending cut proposal
Some of the White House's conservative House allies say they're interpreting the upcoming vote on President Donald Trump's $9.4 billion spending cut proposal as a "test" of what Congress can achieve in terms of rolling back federal funding. Rep. Chip Roy, R-Texas, said he would not speak for members of the Trump administration but added, "I do think it is a test." "And I think this is going to demonstrate whether Congress has the fortitude to do what they always say they'll do," Roy said. "Cut the minimal amount of spending – $9 billion, NPR, PBS, things you complain about for a long time, or are they going to go back into their parochial politics?" House GOP leaders unveiled legislation seeking to codify Trump's spending cut request, known as a rescissions package, on Friday. It's expected to get a House-wide vote sometime next week. Meet The Trump-picked Lawmakers Giving Speaker Johnson A Full House Gop Conference "The rescissions request sent to Congress by the Trump Administration takes the federal government in a new direction where we actually cut waste, fraud, and abuse and hold agencies accountable to the American people," House Majority Leader Steve Scalise, R-La., said in a statement introducing the bill. Read On The Fox News App The legislation would claw back funding that Congress already appropriated to PBS, NPR, and the U.S. Agency for International Development (USAID) – cuts outlined by Elon Musk's Department of Government Efficiency (DOGE) earlier this year. And while several Republican leaders and officials have already said they expect to see more rescissions requests down the line, some people who spoke with Fox News Digital believe the White House is watching how Congress handles this first package before deciding on next steps. "You're dead right," Rep. Ralph Norman, R-S.C., told Fox News Digital when asked if the rescissions package was a test. "I think that it's a test case – if we can't get that…then we're not serious about cutting the budget." A rescissions package only needs simple majorities in the House and Senate to pass. But Republicans in both chambers have perilously slim majorities that afford them few defections. Republicans are also racing the clock – a rescissions package has 45 days to be considered otherwise it is considered rejected and the funding reinstated. Mike Johnson, Donald Trump Get 'Big, 'Beautiful' Win As Budget Passes House Rep. Lance Gooden, R-Texas, did not directly say whether he viewed the spending cuts as a test but dismissed any potential concerns. "This is very low-hanging fruit, and I don't anticipate any problems," Gooden told Fox News Digital. "I've heard a few comments in the media, but I don't think they're serious comments. If someone on the Republican side can make a case for PBS, but they won't take a tough vote against illegal immigration, then we've got a lot of problems." Paul Winfree, president and CEO of the Economic Policy Innovation Center (EPIC), told Fox News Digital last week, "This first rescissions package from President Trump is a test as to whether Congress has the ability to deliver on his mandate by canceling wasteful spending through a filibuster-proof process." "If they can't then it's a signal for the president to turn up the dial with other tools at his disposal," Winfree, who served as Director of Budget Policy in the first Trump administration, said. Both Roy and Norman suggested a process known as "pocket rescissions" could be at least one backup plan – and one that Office of Management and Budget Director Russell Vought has floated himself. "Pocket rescissions" essentially would mean the White House introduces its spending cut proposal less than 45 days before the end of the fiscal year on Sept. 30. In theory, it would run out the clock on those funds and allow them to expire whether Congress acted or not. Vought told reporters after meeting with Speaker Mike Johnson, R-La., on Monday that he wanted to "see if it passes" but was "open" to further rescissions packages. "We want to send up general rescissions bills, to use the process if it's appropriate, to get them through the House and the Senate," Vought said. "We also have pocket rescissions, which you've begun to hear me talk a lot about, to be able to use the end of the fiscal year to send up a similar rescissions, and have the funds expire. So there's a lot of things that we're looking at." Still, some moderate Republicans may chafe at the conservative spending cuts. Rep. Don Bacon, R-Neb., refused to comment on whether he'd support the legislation before seeing the details but alluded to some concerns. "Certainly I'm giving you a non-answer right now until I read the details," Bacon said. "It does bother me because I have a great rapport with Nebraska Public Radio and TV. I think they've been great to work with, and so that would be one I hope they don't put in." He also raised concerns about some specific USAID programs, including critical investments to fight Ebola and HIV in Africa. The legislation is expected to come before the House Rules Committee, the final gatekeeper before most legislation sees a House-wide vote, on Tuesday afternoon. It's separate from Trump's "one big, beautiful bill," a broad piece of legislation advancing the president's tax, energy, and immigration agenda through the budget reconciliation article source: Trump's conservative allies warn Congress faces critical 'test' with $9.4B spending cut proposal
Business Upturn
6 hours ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
16 hours ago
- Yahoo
Earn up to 110,000 bonus miles with a new Delta SkyMiles credit card
American Express and Delta are out with all-new welcome bonus offers across three personal credit cards within the Delta SkyMiles suite: Delta SkyMiles® Gold American Express Card: Earn 80,000 bonus miles after spending $3,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Platinum American Express Card: Earn 90,000 bonus miles after spending $4,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Reserve American Express Card: Earn 100,000 bonus miles after spending $6,000 on eligible purchases in your first six months of card membership. There are also new offers on Delta business cards: Delta SkyMiles® Gold Business American Express Card: Earn 90,000 bonus miles after spending $6,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Platinum Business American Express Card: Earn 100,000 bonus miles after spending $8,000 on eligible purchases in your first six months of card membership. Delta SkyMiles® Reserve Business American Express Card: Earn 110,000 bonus miles after spending $12,000 on eligible purchases in your first six months of card membership. With over 290 destinations across six continents and more than 200 million customers served in 2024, Delta is one of the most well-known airlines worldwide. And you could reduce much of the upfront cost of flying to one of Delta's global destinations if you're able to take advantage of these generous sign-up bonuses. It depends on how you redeem the miles, but we value Delta SkyMiles at an average of 1.18 cents each. That means 100,000 miles equals about $1,180. However, as with many airline credit cards, the exact value of your miles depends on how you use them. Since Delta uses dynamic pricing, you can see different values with each redemption. You can find plenty of value with 100,000 (give or take, depending on the welcome offer) Delta SkyMiles. This is especially true when accounting for the TakeOff 15 benefit, which provides an automatic 15% discount on eligible award flights for Delta SkyMiles cardholders. Let's take a look at some possible redemptions. You can fly from Los Angeles (LAX) to Auckland (AKL) for 38,200 miles. The cash price for the same flight is $1,341, giving you a redemption value of about 3.5 cents per mile ($1,341 / 38,200 = 0.035104). You'll still have plenty of miles left to figure out your return flight, which could mean including a stop in Australia after visiting Hobbiton (and while you're in the area). This flight from Salt Lake City (SLC) to Mexico City (MEX) will only set you back 26,300 miles. The redemption value for this flight is about 1.5 cents per mile, which is better than our average valuation. And with miles to spare, you can bring some friends or work on covering the return leg home. You don't have to get fancy with your redemptions; a short flight will do just fine if it saves you money, especially if it's a route you frequently take. Consider this example: A flight between Atlanta (ATL) and Miami (MIA) that costs 8,300 miles or $117. With 100,000 miles, you could take this flight 12 times, giving you plenty of opportunities for vacations or visiting friends and family. This particular flight has a redemption value of about 1.4 cents per mile. See which flavor — Gold, Platinum, or Reserve — of Delta SkyMiles card is the best fit for you. Consider which Delta SkyMiles business card is right for you if you run a small best Delta SkyMiles credit card for you depends on your goals and spending habits. If you only fly occasionally, maybe a few times per year, we recommend the Delta SkyMiles Gold Amex Card. This card has the lowest annual fee but still provides one of the best benefits: a free checked bag. With only a few roundtrip flights, you can offset the annual fee in saved baggage charges. If you travel a lot, a card like the Delta SkyMiles Platinum Amex Card or Delta SkyMiles Reserve Amex Card may make more sense. These cards have higher annual fees, but they also provide more benefits. For example, the Delta Reserve Amex Card offers Delta Sky Club Access (at least 15 visits each Medallion year), which could come in handy the more you find yourself in airports. Business owners can apply for the personal or business versions of the Delta SkyMiles credit cards. The business credit cards are largely the same as their personal variants, but their welcome offers require increased spending, so keep that in mind when making your decision. All the Delta SkyMiles credit cards associated with these new welcome offers have annual fees. If you want to avoid an annual fee at all costs, consider no-annual-fee credit Disclosure: The information in this article has not been reviewed or approved by any advertiser. All opinions belong solely to the Yahoo Finance and are not those of any other entity. The details on financial products, including card rates and fees, are accurate as of the publish date. All products or services are presented without warranty. Check the bank's website for the most current information. This site doesn't include all currently available offers. Credit score alone does not guarantee or imply approval for any financial product.
